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Abstract: The cumulative risk score (CRS) is a mathematical salivary diagnostic model to define
an individual’s risk of having periodontitis. In order to further validate this salivary biomarker,
we investigated how periodontal bacteria, lipopolysaccharide (LPS), and systemic and local host
immune responses relate to CRS. Subgingival plaque, saliva, and serum samples collected from
445 individuals were used in the analyses. Plaque levels of 28 microbial species, especially
those of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Porphyromonas endodontalis,
Prevotella intermedia, and Tannerella forsythia, and serum and salivary levels of IgA and IgG against
these five species were determined. Additionally, LPS activity was measured. High CRS associated
strongly with all IgA/IgG antibody and LPS levels in saliva, whereas in serum the associations were
not that obvious. In the final logistic regression model, the best predictors of high CRS were saliva IgA
burden against the five species (OR 7.04, 95% CI 2.25–22.0), IgG burden (3.79, 1.78–8.08), LPS (2.19,
1.38–3.47), and the sum of 17 subgingival Gram-negative species (6.19, 2.10–18.3). CRS is strongly
associated with microbial biomarker species of periodontitis and salivary humoral immune responses
against them.
Keywords: biomarkers; bacteria; lipopolysaccharides; saliva; serum
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1. Introduction
Periodontitis, an infection-driven chronic inflammation in tooth-supporting tissues, is highly
common in adults and a major cause of tooth loss. High levels of periodontitis-associated subgingival
bacteria and the humoral immune response to periodontal infection are considered important factors
for the initiation and progression of periodontal disease [1]. In addition to dysbiosis-associated
Gram-negative periodontal pathogens Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis,
Prevotella intermedia, and Tannerella forsythia [2,3], increasing knowledge of polymicrobial synergy and
the development of sequencing techniques have resulted in the discovery of new potential periodontal
pathogens, e.g., Porphyromonas endodontalis [4,5]. Lipopolysaccharide (LPS) of Gram-negative bacteria
is a classical trigger for septic shock, and an independent risk factor for chronic cardiometabolic
disorders [6]. Circulating LPS leads to systemic low-grade inflammation [7]. It has been suggested
that a significant part of the circulating LPS is originated from the oral cavity and that circulating LPS
activity may be a link between periodontitis and coronary artery disease (CAD) [8].
Besides detecting periodontal pathogens directly in saliva or subgingival plaque, the odds for the
pathogen’s presence can be evaluated by measuring the levels of serum or saliva antibodies [1,9–11].
Immunoglobulin A and G (IgA/IgG) are usually determined in this context. Elevated levels of systemic
antibodies against periodontal bacteria have been found in individuals with periodontitis [11–16] and,
thus, serum antibody levels are considered potential diagnostic markers of the disease. According to our
previous studies, IgA and IgG levels in serum associate with P. gingivalis and A. actinomycetemcomitans
carriage in saliva, and the combination of serum antibody levels and salivary pathogen levels improves
the detection of periodontitis [11,17,18]. Due to the local production of antibodies, the antibody levels
against periodontal bacteria are higher in gingival crevicular fluid than in serum. Elevated IgA levels
against A. actinomycetemcomitans and P. gingivalis [10] and IgG levels against A. actinomycetemcomitans
leukotoxins [19] have been observed in the saliva of individuals suffering from periodontitis.
The fluctuating nature of periodontal pathogenesis limits the use of single biomarkers with
established thresholds in the detection of periodontitis [20]. The cumulative risk score (CRS) is a
mathematical model to define an individual’s risk of having periodontitis [21]. Three selected salivary
biomarkers, namely, P. gingivalis, interleukin (IL)-1β, and matrix metalloproteinase (MMP)-8, represent
three components of the periodontal inflammatory process: microbial pathogen burden, cytokine
production, and tissue degradation, respectively. Our previous results indicate that high CRS is
significantly associated with clinical and radiological signs of periodontitis [21–23]. In the present
study, our aim was to validate further the CRS by analyzing its associations with subgingival microbial
biomarker species and salivary humoral immune responses against them.
2. Materials and Methods
2.1. Study Population
The Corogene study is a prospective cohort including Finnish patients who underwent coronary
angiography between June 2006 and March 2008 at the Helsinki University Central Hospital [24].
The Parogene is a sub-study of 508 subjects, who received clinical and radiographic oral health
examinations. As described in detail elsewhere [25,26], these examinations were performed by
calibrated dental specialists. The information of dental hygiene and smoking habits were gathered
with a questionnaire. All subjects signed an informed consent, and the study was approved by the
Helsinki University Central Hospital ethics committee (approval reference number 106/2007, approved
on the 1 August 2007). The present study population consists of the Parogene study patients based on
the availability of their saliva determinations (n = 445, 87.6% of the Parogene cohort).
2.2. Serum and Saliva Samples
Serum samples were drawn from the arterial line during the coronary angiography and stored at
−80 ◦C until further analyses [24]. Saliva samples were collected before the oral examination between
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8 a.m. and 3 p.m. Study participants chewed a piece of paraffin for 5 min, and at least 2 mL of
stimulated whole saliva was collected and stored at −70 ◦C until further use. The samples were
analyzed blindly in the laboratory. After thawing, the samples were centrifuged at 9300× g for 5 min.
The pellets from the process were used for the bacterial analyses, whereas the supernatant was used
for the antibody determinations.
2.3. Measurement of Serum and Saliva Antibodies Against Periodontal Pathogens
An enzyme-linked immunosorbent assay (ELISA) [11,27] was used to determine serum levels
of IgA and IgG against whole cell antigens of A. actinomycetemcomitans, P. gingivalis, P. endodontalis,
P. intermedia, and T. forsythia. The details of these analyses are described elsewhere [18,28]. Salivary
levels of IgA/IgG against the same whole cell antigens of the same species were analyzed using a
chemiluminescence immunoassay as described in detail elsewhere [29]. The antigens used in the
assays, dilutions, and inter-assay variations are presented in Supplementary Table (Table S1).
2.4. Subgingival Bacteria
Pooled subgingival plaque samples were collected from the deepest pocket of each jaw
quadrant [30]. Checkerboard DNA–DNA hybridization was used to determine the levels of 28 bacterial
species, and of these, the levels of the same five species used for the antibody determinations were
selected for detailed analyses [31,32]. Additionally, a sum level of 17 Gram-negative (P. gingivalis,
T. forsythia, T. denticola, A. actinomycetemcomitans (strains Y4 plus ATCC 29523), P. intermedia,
Fusobacterium nucleatum ssp. naviforme, F. nucleatum ssp. nucleatum, F. nucleatum ssp. polymorphum,
F. periodonticum, Campylobacter rectus, C. gracilis, C. showae, Veillonella parvula, Capnocytophaga gingivalis,
C. sputigena, C. ochracea, and Eikenella corrodens) and 11 Gram-positive species (Parvimonas micra,
Actinomyces odontolyticus, A. israelii, A. naeslundii, A. neuii, Streptococcus mitis, S. oralis, S. sanguinis,
S. gordonii, S. intermedius, and S. constellatus) [32] were used in the statistical analyses.
2.5. LPS Activity in Serum and Saliva Samples
After diluting the samples with endotoxin-free water, the LPS activity was determined from the
serum samples (1:5, v/v) and the saliva supernatant (1:40.000, v/v) by a commercially available
assay, Limulus amebocyte lysate coupled with a chromogenic substrate (Hycult Biotec, Uden,
The Netherlands). The inter-assay coefficient of variation was 5.5% for serum and 6.8% for the
saliva samples.
2.6. CRS Determination
The CRS values of the present study population have been described previously [23]. Briefly,
the concentrations of IL-1β and aMMP-8 were determined from the saliva supernatants and the quantity
ofP. gingivalis from the saliva pellets. IL-1β concentrations were determined with a flow cytometry-based
technique (MILLIPLEX® Map Kit, Human Cytokine/Chemokine panel MPXHCYTO-60K, Millipore,
Billerica, MA, USA and Luminex® xMAP™ technique, Luminex Corporation, Austin, TX, USA),
and MMP-8 concentrations with a time-resolved immunofluorometric assay (IFMA), as described
by Gürsoy et al. [33] A qPCR-based technique was used to quantitate P. gingivalis in saliva and the
concentrations were calculated as genomic equivalents (GE)/mL [28]. All concentrations were divided
into tertiles to achieve a cumulative sub-score for each study subject. These sub-scores were further
multiplied with each other and used to categorize the study population with “low (CRS I), moderate
(CRS II), or high (CRS III) risk of having periodontitis”. A detailed methodological description of CRS
and its diagnostic abilities to detect periodontitis has been published elsewhere [21,23].
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2.7. Statistical Analyses
Statistical analyses were performed with the statistical program (SPSS version 21.0; SPSS Inc.,
Chicago, IL, USA). The data were not normally distributed and therefore are presented in medians
with interquartile range (IQR). The chi-square test was used when examining the relation of
gender, proportion of edentulous, ever smoked, and diabetes mellitus (type 1 and 2) to CRS I–III.
The Jonckheere–Terpstra test was used when examining the linear relation of CRS I–III with age,
number of teeth, serum or saliva IgA/IgG, LPS activity, and subgingival bacterial levels. Logistic
regression models were used when the association of high CRS (III vs. CRS I–II) with serum or
saliva IgA/IgG and LPS activity, and subgingival bacteria levels was examined. Firstly, the models
were adjusted for age, gender, and number of remaining teeth, and, if found significant, they were
additionally adjusted for the subgingival level of the corresponding bacterial species. The associations
of high CRS (CRS III vs. CRS I–II) with antibody, LPS, and bacterial levels were analyzed in multiple
logistic regression models adjusted for age, sex, number of teeth, and smoking (ever vs. never).
To standardize the values, all models were performed for logarithmically (10-base) transformed results.
The p-value < 0.05 was considered significant.
3. Results
Table 1 shows the characteristics of the population in relation to CRS I–III. As expected, there
were statistically significant differences in the number of teeth and periodontal status between the
CRS groups.
Table 1. Characteristics of the study population divided into three groups on the basis of cumulative
risk score (CRS) I–III.
CRS I CRS II CRS III
Median (IQR) p-Value 1
Age (years) 66 (10) 64 (14) 63 (13) 0.054
Number of teeth 21 (18) 24 (11) 24 (8) 0.001
n (%) p-Value 2
Sex (% of men) 70 (58.8) 119 (71.3) 114 (66.3) 0.091
Ever smoked 57 (48.3) 96 (57.5) 89 (51.7) 0.286
Diabetes 26 (21.8) 33 (20.2) 51 (30.0) 0.089
Periodontal and dental status 3 <0.001
No to mild periodontitis 88 (74.6) 125 (74.0) 102 (59.3)
Moderate to severe periodontitis 15 (12.7) 36 (21.3) 67 (39.0)
Edentulous 15 (12.7) 8 (4.7) 3 (1.7)
1 p-values from the Jonckheere–Terpstra test; 2 chi-square tests; 3 the classification is based on alveolar bone loss and
periodontal probing pocket depth as reported in our previous study [23]. Results are presented as median values
with interquartile range (IQR). Significant p-values are indicated in bold face.
Serum antibody and LPS activity levels in relation to CRS I–III are presented in Table 2. Elevating
IgA levels against P. gingivalis, P. endodontalis, and P. intermedia and elevating IgG levels against
P. gingivalis, P. endodontalis, and P. intermedia were found with increasing CRS, whereas the T. forsythia
antibody levels or serum LPS activity did not differ between CRS I–III. In regression analyses,
after adjusting for age, sex, and number of teeth (Model 1), high CRS (III) associated significantly
with the IgA levels against A. actinomycetemcomitans, P. gingivalis, P. endodontalis, and P. intermedia and
the IgG levels against P. gingivalis, P. endodontalis, and P. intermedia. When the models were further
adjusted for the corresponding subgingival bacterial level, A. actinomycetemcomitans IgA, P. gingivalis
IgG, P. endodontalis IgA/IgG, and P. intermedia IgA remained significantly associated with CRS III.
Saliva antibody and LPS activity levels in relation to CRS are presented in Table 3. The IgA/IgG
antibody levels against all tested bacteria and LPS activity were elevating with increasing CRS. In logistic
regression analyses adjusted for age, sex, and number of teeth (Model 1), high CRS (III) associated
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significantly with all IgA/IgG and LPS activity levels. These associations remained significant when
the models were adjusted further for the corresponding subgingival bacterial level (the antibodies)
or the sum of Gram-negative bacteria (LPS).
Subgingival bacterial levels in relation to CRS I–III are presented in Table 4. The counts of all
examined bacteria, and the sum of 11 subgingival Gram-positive and 17 subgingival Gram-negative
species increased with increasing CRS. In the association analyses adjusted for age, gender, and number
of remaining teeth, high CRS (III) associated significantly with all examined bacterial species, and with
the sum of 11 subgingival Gram-positive and 17 subgingival Gram-negative species.
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Table 2. Serum antibody levels in response to five periodontal pathogens and lipopolysaccharide (LPS) levels according to the CRS.
Antigen/Measure Antibody Class CRS I n = 117 CRS II n = 162 CRS III n = 166 p-Value 1 OR for High CRS (95% CI), p-Value 2
Median (IQR) Model 1 Model 2
Aggregatibacteractinomycetemcomitans IgA 0.61 (0.61) 0.59 (0.67) 0.69 (0.69) 0.037 2.22 (1.19–4.18), 0.012 2.39 (1.27–4.52), 0.007
IgG 0.60 (0.50) 0.69 (0.80) 0.73 (0.77) 0.043 1.66 (0.92–3.00), 0.094
Porphyromonas gingivalis IgA 0.24 (0.98) 0.33 (0.91) 0.86 (1.41) <0.001 2.88 (1.89–4.38) <0.001 1.47 (0.92–2.35), 0.106
IgG 0.84 (1.47) 0.95 (1.37) 1.71 (1.88) <0.001 7.34 (3.65–14.7), <0.001 2.32 (1.04–5.18), 0.040
Porphyromonas endodontalis IgA 0.33 (0.55) 0.45 (0.61) 0.65 (1.26) <0.001 3.52 (2.03–6.09), <0.001 2.95 (1.66–5.21), <0.001
IgG 0.97 (1.31) 1.12 (1.17) 1.79 (1.66) <0.001 7.41 (3.36–16.3), <0.001 6.08 (2.94–12.3), <0.001
Prevotellaintermedia IgA 0.56 (0.41) 0.56 (0.44) 0.68 (0.60) 0.013 3.11(1.43–6.74), 0.004 2.59 (1.15–5.81), 0.021
IgG 0.44 (0.35) 0.42 (0.28) 0.46 (0.35) 0.295 2.30 (1.01–5.22), 0.047 1.87 (0.79–4.42), 0.154
Tannerella forsythia IgA 0.23 (0.16) 0.18 (0.12) 0.19 (0.14) 0.114 1.28 (0.65–2.53), 0.474
IgG 0.12 (0.13) 0.10 (0.11) 0.10 (0.12) 0.203 1.06 (0.57–1.97), 0.855
LPS 0.46 (0.43) 0.54 (0.62) 0.53 (0.58) 0.123 1.23 (0.68–2.22), 0.497
1 Jonckheere–Terpstra test; 2 logistic regression models, dependent variable CRS III vs. CRSI–II, odds ratio (OR) is presented/10-base logarithmically transformed unit; Model 1, adjusted
for age, gender, and number of remaining teeth; Model 2, additionally adjusted for the subgingival level of the species. The antibody levels are presented as absorbance units, AU. The LPS
activity is presented as endotoxin units, EU/mL. Statistically significant p-values are indicated by bold face.
Table 3. Saliva antibody levels in response to five periodontal pathogens and lipopolysaccharide (LPS) levels according to the CRS.
Antigen/Measure Antibody Class CRS I n = 108 CRS II n = 155 CRS III n = 157 p-Value 1 OR for High CRS (95% CI), p-Value 2
Median (IQR) Model 1 Model 2
A. actinomycetemcomitans IgA 2843 (2221) 3413 (3065) 4403 (5569) <0.001 6.02 (3.06–11.8),
<0.001
6.24 (3.11–12.5),
<0.001
IgG 4160 (4669) 7642 (15,265) 14,154 (40,410) <0.001 3.28 (2.22–4.87),
<0.001
3.26 (2.17–4.89),
<0.001
P. gingivalis IgA 3587 (5609) 5217 (5642) 9340 (12,507) <0.001 6.72 (3.74–12.1),
<0.001
4.50 (2.41–8.41),
<0.001
IgG 1500 (2254) 2647 (4725) 6111 (11,734) <0.001 5.97 (3.72–9.61),
<0.001
3.76 (2.26–6.25),
<0.001
P. endodontalis IgA 4809 (3249) 6971 (6315) 10,146 (9454) <0.001 16.8 (7.50–37.5),
<0.001
14.5 (6.36–32.8),
<0.001
IgG 1511 (1377) 2482 (2445) 4546 (5769) <0.001 13.9 (7.11–27.3),
<0.001
13.7 (6.89–27.4),
<0.001
P. intermedia IgA 2014 (1880) 3026 (2637) 3878 (4885) <0.001 5.90 (3.04–11.4),
<0.001
5.97 (3.01–11.8),
<0.001
IgG 1069 (637) 1534 (1755) 2547 (3284) <0.001 10.2 (5.16–20.6),
<0.001
10.0 (5.03–20.1),
<0.001
T. forsythia IgA 5893 (4254) 7849 (6614) 8359 (6605) <0.001 5.43 (2.39–12.3),
<0.001
6.92 (2.87–16.5),
<0.001
IgG 1448 (1069) 2208 (2712) 3956 (4397) <0.001 7.83 (4.13–14.8),
<0.001
8.81 (4.44–17.5),
<0.001
LPS activity 3991 (8406) 4825 (10,816) 9065 (14,866) <0.001 2.40 (1.600–3.591),0.001
2.42 (1.568–3.728),
<0.001 3
1 Jonckheere–Terpstra test; 2 logistic regression models, dependent variable CRS III vs. CRSI–II, OR is presented/10-base logarithmically transformed unit; Model 1, adjusted for age, sex,
and number of teeth; Model 2, additionally adjusted for the subgingival level of the species; 3 additionally adjusted for the sum of 17 Gram-negative subgingival species. The antibodies are
presented as relative light units, RLU/100 ms. The LPS activity is presented as endotoxin units, EU/mL. Statistically significant p-values are indicated by bold face.
Diagnostics 2020, 10, 560 7 of 12
Table 4. Subgingival bacterial levels according to the CRS groups.
Species (Counts × 105) CRS I CRS II CRS III p-Value 1 OR for High CRS (95% CI), p-Value 4
Median (IQR)
A. actinomycetemcomitans 0.32 (1.12) 0.45 (1.58) 0.79 (1.92) <0.001 1.85 (1.43–2.39), <0.001
P. gingivalis 0.26 (0.77) 0.38 (1.71) 2.95 (12.7) <0.001 2.70 (2.11–3.46), <0.001
P. endodontalis 0.07 (0.94) 0.22 (1.31) 1.10 (4.30) <0.001 1.97 (1.57–2.47), <0.001
P. intermedia 0.47 (1.42) 0.57 (1.98) 1.55 (3.07) <0.001 1.95 (1.53–2.49), <0.001
T. forsythia 1.95 (9.28) 3.47 (11.1) 12.9 (24.8) <0.001 2.00 (1.63–2.46), <0.001
Sum of Gram positive species 2 4.24 (8.71) 4.75 (14.3) 9.82 (12.5) <0.001 2.25 (1.52–3.34), <0.001
Sum of Gram negative species 3 25.0 (48.9) 35.0 (67.1) 70.6 (67.6) <0.001 3.28 (2.10–5.13), <0.001
1 Jonckheere–Terpstra test; 2 sum of 11 subgingival species; 3 sum of 17 subgingival species; 4 logistic regression model, dependent variable CRS III vs. CRSI–II, OR is presented/10-base
logarithmically transformed unit, adjusted for age, sex, and number of teeth. Statistically significant p-values are indicated by bold face.
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Table 5 summarizes the associations of high CRS (III) with antibody and bacterial levels in a
regression model that was adjusted for age, gender, number of teeth, and smoking. Salivary IgA
burden against the five species, salivary IgG burden against the five species, salivary LPS, and the sum
of subgingival Gram-negative species associated with high CRS. The odds ratios were 7.04 (p = 0.001),
3.79 (p = 0.001), 2.19 (p = 0.001), and 6.19 (p = 0.001), respectively.
Table 5. Association of high CRS with antibody and subgingival bacterial levels.
Variable Unit OR (95% CI) for HighCRS p-Value
1
Covariates
Age years 0.997 (0.975–1.019) 0.779
Sex male 0.965 (0.640–1.455) 0.865
Number of teeth number 1.034 (1.008–1.061) 0.011
Smoking ever 1.055 (0.703–1.583) 0.796
Model
Serum
Serum IgA burden 2 EU 0.910 (0.259–3.197) 0.883
Serum IgG burden 2 EU 2.949 (0.536–16.23) 0.214
Serum LPS EU/mL 1.396 (0.681–2.860) 0.362
Saliva
Saliva IgA burden 2 RLU/100 ms 7.043 (2.252–22.03) 0.001
Saliva IgG burden 2 RLU/100 ms 3.788 (1.777–8.077) 0.001
Saliva LPS EU/mL 2.191 (1.384–3.468) 0.001
Subgingival Sum of Gram-positive species
3 count × 105 0.641 (0.266–1.547) 0.322
Sum of Gram-negative species 4 count × 105 6.191 (2.098–18.27) 0.001
1 Logistic regression model, dependent variable CRS III vs. CRS I–II, model is adjusted for covariates presented
above. For the bacteria, Ig, and LPS levels, OR is presented/10-base logarithmically transformed unit; 2 sum of
antibody levels in response to A. actinomycetemcomitans, P. gingivalis, P. endodontalis, P. intermedia, and T. forsythia;
3 sum of 11 subgingival species; 4 sum of 17 subgingival species; 5 presented as counts × 105 EU, ELISA units;
EU/mL, endotoxin units/mL; RLU, relative light units. Statistically significant p-values are indicated by bold face.
4. Discussion
Here we present a strong association of salivary IgA burden, salivary IgG burden, salivary
LPS, and the sum of subgingival Gram-negative species with high CRS. Due to its associations with
subgingival periodontal bacteria and the salivary humoral immune response to them, the present
findings produce additional evidence on the diagnostic strength of CRS.
Our study shows for the first time that LPS activity in saliva associates with a risk of having
periodontitis, based on CRS. We used the Limulus Amebocyte lysate assay to measure LPS activity in
saliva and serum, because it is the most sensitive and most widely used method [34]. The assay is not
targeted to any specific bacterial species but determines the overall biological activity of a mixture of
endotoxins produced by Gram-negative bacteria. It has been shown that serum LPS correlates with
periodontal status and serum LPS activity decreases after periodontal treatment [35–37]. A significant
part of circulating LPS may originate from the oral cavity. There is supporting evidence that there is a
correlation between serum and saliva LPS activity levels [8]. Moreover, a study performed with mice
estimated that oral administration of P. gingivalis could change the gut microbiome and lead to elevated
serum endotoxin levels [38]. In investigations on structural alterations in lipid-A-derived 3-OH fatty
acid profiles or using a bioassay for Toll-like receptors 2 and 4, stimulants indicate that there are
differences in saliva between individuals with and without periodontal disease [39,40]. These methods
differ from the LAL assay and do not measure the activity level of LPS. Based on our previous data
on LPS activity in saliva, LPS activity correlates with the number of remaining teeth and the amount
of alveolar bone loss; however, no relation to clinical periodontal parameters was found [8,28,41].
Similarly, in the present study, no association between serum LPS and CRS was observed.
To date, findings on IgA/IgG binding to periodontal bacteria in saliva are limited to
A. actinomycetemcomitans,P. gingivalis,T. denticola,P. intermedia, andF. nucleatum [10,42–44]. In the present
population, we also determined the salivary antibodies against T. forsythia and P. endodontalis [28,45].
Elevated salivary levels of IgA antibodies against A. actinomycetemcomitans and P. gingivalis [10] and
salivary IgG levels against A. actinomycetemcomitans leukotoxins [19] have been detected in periodontitis
patients. Since all determined salivary antibody levels associated with CRS, we calculated their sum
to be used in further statistical analyses and to strengthen the association. Notably, salivary IgA/IgG
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burden against these microbial biomarker species presented an independent and strong association
with CRS even in models where the bacterial subgingival levels were used as covariates. This indicates
immune hyperresponsiveness to dysbiosis, typical for the pathogenesis of periodontitis [46].
Elevated levels of systemic antibodies against periodontal bacteria are common in periodontitis
patients [12,14–16,47]. Conceivably, it can be assumed that there is a connection between CRS and
systemic IgA/IgG response. In this study, high CRS (III) associated significantly with the serum IgA
levels against A. actinomycetemcomitans, P. endodontalis, and P. intermedia and with the IgG levels against
P. gingivalis and P. endodontalis. Based on the association analyses, these serum antibody levels were also
independent of the subgingival bacterial level. Interestingly, the most significant association with high
CRS was observed with antibodies against P. gingivalis and P. endodontalis. An obvious explanation is
that CRS already includes P. gingivalis concentration and, in the case of P. endodontalis, cross-reactivity of
antibodies to P. endodontalis and closely related species cannot be excluded. The results regarding serum
antibodies and CRS are in line with our previous observations on the associations with serum IgA/IgG
levels of P. gingivalis and A. actinomycetemcomitans and their carriage in saliva, whereas periodontitis
proved to have merely a modest modifying effect [11]. Furthermore, the impact of the variation of
serum antibody response between individuals in relation to genetic and immunological background,
previous exposure to periodontal bacteria, and immunogenic characteristics of the antigenic challenge
have been discussed [48]. IgG antibodies with a long half-life represent exposure to the bacteria;
however, these antibodies are extremely stable in plasma and do not allow an estimation of the time of
the exposure [13,49]. Instead, IgA antibodies with a short half-time represent a recent or continuous
exposure to the indicated pathogen [50]. Therefore, it seems that saliva, in comparison to serum, would
be a more suitable specimen type to recognize biomarkers of active periodontal inflammation.
The relatively large sample size (n = 445) and verified background data on general and oral
health are the major strengths of the present study. The suitability of CRS for the evaluation of the
risk of having periodontitis is established in previous studies [21–23]. Here we demonstrated the
connection of CRS with subgingival bacterial levels as well as with antibodies against periodontal
bacteria and LPS activity in saliva samples. On the other hand, a weakness of the present research
is that the study population consists of patients with symptomatic heart disease, including stable
coronary artery disease, acute coronary syndrome, stable or atypical chest pains, valvular heart disease,
or cardiomyopathy. Thus, especially when evaluating the levels of serum antibodies, the results may
not be fully applicable to a general population. Additionally, the subgingival plaque sample collected
from each dental quadrant was pooled into one sample per patient. While the samples were taken
from the deepest pockets, the pool may not necessarily represent the whole mouth.
5. Conclusions
Our new findings suggest that CRS is a reliable and suitable diagnostic tool for periodontitis.
The results reveal how the salivary biomarker combination, CRS, reflects the presence of dysbiotic
subgingival biofilms and the local host response to periodontal pathogens and, further, validate CRS in
saliva-based diagnostics on the road to more personalized dentistry.
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